Last modified by Sarantis Dimitriadis on 2023/12/08 13:20
From version 5.10
edited by Sarantis Dimitriadis
on 2022/06/07 10:20
Change comment: There is no comment for this version
To version 7.1
edited by Sarantis Dimitriadis
on 2023/05/30 09:35
Change comment: There is no comment for this version

Summary

Details

Page properties
Content
... ... @@ -7,7 +7,7 @@
7 7  (% class="western" lang="en-GB" style="text-align:justify" %)
8 8  (% lang="en-US" %)End users can be classified to non-professional and professional groups. Typical non-professional and professional end-user groups in health and wellbeing includes the following:
9 9  
10 -:
10 +:
11 11  
12 12  * (((
13 13  (% lang="en-US" %)**Non-professional end users:**
... ... @@ -17,7 +17,7 @@
17 17  * (% lang="en-US" %)**Public health and social service clients: **Those who use public services.
18 18  )))
19 19  
20 -:
20 +:
21 21  
22 22  * (((
23 23  (% lang="en-US" %)**Professional end users**
... ... @@ -29,12 +29,12 @@
29 29  * (% lang="en-US" %)**Policy and decisions makers:** Those responsible for making policies and decisions at local, regional, national or international level.
30 30  )))
31 31  
32 -:
32 +:
33 33  
34 34  (% class="western" lang="en-GB" %)
35 35  (% lang="en-US" %)**Business-to-Business Customer (B2B):** B2B-customer is an organization that purchases living lab services from a living lab. B2B-customers can be classified to private, public, education/ research, civil society organizations and networks/cluster groups as follows:
36 36  
37 -:
37 +:
38 38  
39 39  * (((
40 40  (% lang="en-US" %)**Private sector organizations: **(business developers and researchers)
... ... @@ -50,7 +50,7 @@
50 50  * (% lang="en-US" %)Pharmaceutical companies
51 51  )))
52 52  
53 -:
53 +:
54 54  
55 55  * (((
56 56  (% lang="en-GB" %)
... ... @@ -67,7 +67,7 @@
67 67  * (% lang="en-US" %)**Public funder:** Government or other European, national, regional or local public institutions who is providing public funding for a specific living lab living lab research project via call for application process.
68 68  )))
69 69  
70 -:
70 +:
71 71  
72 72  * (((
73 73  (% lang="en-GB" %)
... ... @@ -82,7 +82,7 @@
82 82  * (% lang="en-US" %)**Private research organizations** such as technology and innovation centers
83 83  )))
84 84  
85 -:
85 +:
86 86  
87 87  * (((
88 88  (% lang="en-GB" %)
... ... @@ -91,7 +91,7 @@
91 91  * (% lang="en-US" %)Non-governmental organizations (NGO) and nonprofit entities operating at international, national, regional or local level.
92 92  )))
93 93  
94 -:
94 +:
95 95  
96 96  * (((
97 97  (% lang="en-GB" %)
... ... @@ -104,13 +104,10 @@
104 104  :
105 105  
106 106  (% class="western" lang="en-GB" %)
107 -(% lang="en-US" %)Typical approaches to define (%%)non-professional end users (a.k.a. study participants) in health and wellbeing living lab projects are presented in Table .
107 +(% lang="en-US" %)Typical approaches to define (%%)non-professional end users (a.k.a. study participants) in health and wellbeing living lab projects are presented in the following table .
108 108  
109 -(% style="margin-left:auto; margin-right:auto" %)
110 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:11px; text-align:center; vertical-align:middle; width:634px" %)(((
111 -(% class="western" lang="en-GB" style="text-align:center" %)
112 -(% lang="en-US" %)**Age or age group**
113 -)))
109 +(% style="height:1004px; margin-left:auto; margin-right:auto; width:1694px" %)
110 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:11px; text-align:center; vertical-align:middle; width:634px" %)**Age groups**
114 114  |(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)(((
115 115  (% lang="en-US" %)Specific age range
116 116  )))|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)(((
... ... @@ -122,145 +122,47 @@
122 122  (% class="western" %)
123 123  
124 124  )))
125 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)(((
126 -(% class="western" lang="en-GB" %)
127 -(% lang="en-US" %)Elderly
128 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)(((
129 -(% class="western" lang="en-GB" %)
130 -(% lang="en-US" %)Adults
131 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)(((
132 -(% class="western" lang="en-GB" %)
133 -(% lang="en-US" %)Youth
134 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)(((
135 -(% class="western" lang="en-GB" %)
136 -(% lang="en-US" %)Children
137 -)))
122 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)Adolescents|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)Adults|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)Older Adults|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)General Population
138 138  |(% colspan="4" style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; vertical-align:top; width:634px" %)(((
139 139  (% class="western" %)
140 140  
141 141  )))
142 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)(((
143 -(% class="western" lang="en-GB" style="text-align:center" %)
144 -(% lang="en-US" %)**Health status**
145 -)))
127 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)**Adolescents Health status (disease, disorder or disability)**
146 146  |(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)(((
147 147  (% class="western" lang="en-GB" %)
148 148  (% lang="en-US" %)Healthy
149 149  )))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)(((
150 150  (% class="western" lang="en-GB" %)
151 -(% lang="en-US" %)Patient
133 +
152 152  )))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:153px" %)(((
153 153  (% class="western" lang="en-GB" %)
154 -(% lang="en-US" %)Rehabilitant
136 +
155 155  )))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:justify; vertical-align:middle; width:152px" %)(((
156 156  (% class="western" lang="en-GB" %)
157 -(% lang="en-US" %)Recovered/Survivor
139 +
158 158  )))
159 159  |(% colspan="4" style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; vertical-align:top; width:634px" %)(((
160 160  (% class="western" %)
161 161  
162 162  )))
163 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)(((
164 -(% class="western" lang="en-GB" style="text-align:center" %)
165 -(% lang="en-US" %)**A specific disease, disorder or disability**
166 -)))
167 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
168 -(% class="western" lang="en-GB" %)
169 -(% lang="en-US" %)ADHD
170 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
171 -(% class="western" lang="en-GB" %)
172 -(% lang="en-US" %)Dementia
173 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
174 -(% class="western" lang="en-GB" %)
175 -(% lang="en-US" %)Parkinsons’ disease
176 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
177 -(% class="western" lang="en-GB" %)
178 -(% lang="en-US" %)Loneliness and Social Isolation
179 -)))
180 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
181 -(% class="western" lang="en-GB" %)
182 -(% lang="en-US" %)Autism
183 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
184 -(% class="western" lang="en-GB" %)
185 -(% lang="en-US" %)Down syndrome
186 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
187 -(% class="western" lang="en-GB" %)
188 -(% lang="en-US" %)Physical disability
189 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
190 -(% class="western" lang="en-GB" %)
191 -(% lang="en-US" %)Mental health
192 -)))
193 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
194 -(% class="western" lang="en-GB" %)
195 -(% lang="en-US" %)Cardiovascular disease
196 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
197 -(% class="western" lang="en-GB" %)
198 -(% lang="en-US" %)Idiopathic pulmonary fibrosis (IPF)
199 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
200 -(% class="western" lang="en-GB" %)
201 -(% lang="en-US" %)Sleep apnea/apnea
202 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
203 -(% class="western" lang="en-GB" %)
204 -(% lang="en-US" %)Mild cognitive impairment
205 -)))
206 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
207 -(% class="western" lang="en-GB" %)
208 -(% lang="en-US" %)Chronic Obstructive Pulmonary Disease (COPD)
209 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
210 -(% class="western" lang="en-GB" %)
211 -(% lang="en-US" %)Language disability
212 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
213 -(% class="western" lang="en-GB" %)
214 -(% lang="en-US" %)Substance abuse (drugs, alcohol)
215 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
216 -(% class="western" lang="en-GB" %)
217 -(% lang="en-US" %)Multiple sclerosis
218 -)))
219 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
220 -(% class="western" lang="en-GB" %)
221 -(% lang="en-US" %)Cognitive disorder (mild, major)
222 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
223 -(% class="western" lang="en-GB" %)
224 -(% lang="en-US" %)Intellectual disability/ Learning difficulty/ Mental retardation
225 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
226 -(% class="western" lang="en-GB" %)
227 -(% lang="en-US" %)Trauma patient
228 -
229 -(% class="western" lang="en-GB" %)
230 -(% lang="en-US" %)(e.g., a spinal cord injury)
231 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
232 -(% class="western" lang="en-GB" %)
233 -(% lang="en-US" %)Neurodegenerative diseases
234 -)))
145 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)**Adults Health status (disease, disorder or disability)**
146 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)Healthy|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)Schizophrenia|Multiple-Sclerosis|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)Parkinson Disease
147 +|(% style="height:30px; width:153px" %)Post-Stroke Patients with Moving or Linguistic Disability|Mild Cognitive Impairment|Sleep Disorders: e.g., Apnea, Hypopnea|With Disability
148 +|Healthy with Possible Chronic Conditions|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %) |(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %) |(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)
235 235  |(% colspan="4" style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; vertical-align:top; width:634px" %)(((
236 236  (% class="western" %)
237 237  
238 238  )))
239 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)(((
240 -(% class="western" lang="en-GB" style="text-align:center" %)
241 -(% lang="en-US" %)**Clients of a specific service**
242 -)))
243 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
244 -(% class="western" lang="en-GB" %)
245 -(% lang="en-US" %)Child welfare
246 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
247 -(% class="western" lang="en-GB" %)
248 -(% lang="en-US" %)Nursing home
249 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
250 -(% class="western" lang="en-GB" %)
251 -(% lang="en-US" %)Employment service
252 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
153 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)**Older Adults Health status (disease, disorder or disability)**
154 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)Healthy|Parkinson Disease|Mild Cognitive Impairment|With Disability|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
253 253  (% class="western" %)
254 254  
255 255  )))
256 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
158 +|(% style="height:30px; width:153px" %)Healthy with Possible Chronic Conditions|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
257 257  (% class="western" lang="en-GB" %)
258 -(% lang="en-US" %)Early childhood education
160 +
259 259  )))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
260 260  (% class="western" lang="en-GB" %)
261 -(% lang="en-US" %)Home care
262 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
263 -(% class="western" lang="en-GB" %)
264 264  
265 265  )))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
266 266  (% class="western" lang="en-GB" %)
... ... @@ -270,70 +270,20 @@
270 270  (% class="western" %)
271 271  
272 272  )))
273 -|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)(((
274 -(% class="western" lang="en-GB" style="text-align:center" %)
275 -(% lang="en-US" %)**Vulnerable groups**
276 -)))
277 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
172 +|(% colspan="4" style="border-color:#000000 currentcolor; border-style:solid none; border-width:1px medium; height:30px; text-align:center; vertical-align:middle; width:634px" %)**General Population Health status (disease, disorder or disability)**
173 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)Healthy|Ipf Patients|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)Prostate Cancer|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
278 278  (% class="western" lang="en-GB" %)
279 -(% lang="en-US" %)Minors/Children
280 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
281 -(% class="western" lang="en-GB" %)
282 -(% lang="en-US" %)Single parents with minor children
283 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
284 -(% class="western" lang="en-GB" %)
285 -(% lang="en-US" %)Persons subjected to psychological, physical or sexual violence
286 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
287 -(% class="western" lang="en-GB" %)
288 -(% lang="en-US" %)Substance users
289 -
290 -(% class="western" lang="en-GB" %)
291 -(% lang="en-US" %)(drugs, alcohol)
175 +Down Syndrome
292 292  )))
293 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)(((
177 +|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:left; vertical-align:middle; width:153px" %)Chronical Diseases: e.g., Persons With Chronic Pulmonary (Copd)|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)Cardiological Or Other Conditions (Aphasia)|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)Breast Cancer Survivors|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
294 294  (% class="western" lang="en-GB" %)
295 -(% lang="en-US" %)Disabled people
296 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
297 -(% class="western" lang="en-GB" %)
298 -(% lang="en-US" %)Victims of trafficking in human beings
299 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
300 -(% class="western" lang="en-GB" %)
301 -(% lang="en-US" %)Ethnic minorities and immigrants
302 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
303 -(% class="western" lang="en-GB" %)
304 -(% lang="en-US" %)Isolated people
305 -)))
306 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:30px; text-align:justify; vertical-align:middle; width:153px" %)(((
307 -(% class="western" lang="en-GB" %)
308 -(% lang="en-US" %)Elderly people
309 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
310 -(% class="western" lang="en-GB" %)
311 -(% lang="en-US" %)Persons with serious illnesses
312 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
313 -(% class="western" lang="en-GB" %)
314 -(% lang="en-US" %)Homeless people
315 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
316 -(% class="western" lang="en-GB" %)
317 -(% lang="en-US" %)Ex-prisoners and people with criminal background
318 -)))
319 -|(% style="border-color:currentcolor; border-style:none; border-width:medium; height:12px; text-align:left; vertical-align:middle; width:153px" %)(((
320 -(% class="western" lang="en-GB" %)
321 -(% lang="en-US" %)Pregnant women
322 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
323 -(% class="western" lang="en-GB" %)
324 -(% lang="en-US" %)Persons with mental disorders
325 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:153px" %)(((
326 -(% class="western" lang="en-GB" %)
327 327  
328 -)))|(% style="border-color:currentcolor; border-style:none; border-width:medium; text-align:left; vertical-align:middle; width:152px" %)(((
329 -(% class="western" lang="en-GB" %)
330 -
331 331  )))
332 332  
333 333  :
334 334  
335 335  (% class="western" lang="en-GB" %)
336 -(% lang="en-US" style="page-break-before:always" %)Living lab research infrastructure end users and B2B-customers (% style="page-break-before:always" %)in health and wellbeing living lab projects are presented in Table .
185 +(% lang="en-US" style="page-break-before:always" %)Living lab research infrastructure end users and B2B-customers (% style="page-break-before:always" %)in health and wellbeing living lab projects are presented in (%%)the table below(% style="page-break-before:always" %) .
337 337  
338 338  |**Researcher expertise**|**Brief use case description**
339 339  |Policy Makers|Studying the impact of new service models or new collaboration models in healthcare, designing or improving policies, gathering requirements for improving health and wellbeing of citizens, co-creation of research methodologies for policy making

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101007990

Copyright © 2021 VITALISE Project